Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).

"The book offers a beautiful journey to explore the application of AI and ML in DrugDevelopment. Even though it cannot replace academic courses in AI, ML andhealthcare,authors provide very important and interesting updates regarding the evolution andadvances achieved in this field the past 10 years."Ramzi El Feghali, ISCB News, May 2024.

• 1 Transforming Pharma with Data Science, AI and Machine Learning 2 Regulatory Perspective on Big Data, AI, and Machining Learning 3 Building an Agile and Scalable Data Science Organization 4 AI and Machine Learning in Drug Discovery 5 Predicting Anti-Cancer Synergistic Activity Through Machine Learning and Natural Language Processing 6 AI-Enabled Clinical Trials 7 Machine Learning for Precision Medicine 8 Reinforcement Learning in Personalized Medicine 9 Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance 10 Intelligent Manufacturing and Supply of Biopharmaceuticals 11 Reinventing Medical Affairs in the Era of Big Data and Analytics 12 Deep Learning with Electronic Health Record 13 Real-World Evidence for Treatment Access and Payment Decisions

Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).

"The book offers a beautiful journey to explore the application of AI and ML in DrugDevelopment. Even though it cannot replace academic courses in AI, ML andhealthcare,authors provide very important and interesting updates regarding the evolution andadvances achieved in this field the past 10 years."Ramzi El Feghali, ISCB News, May 2024.

• 1 Transforming Pharma with Data Science, AI and Machine Learning 2 Regulatory Perspective on Big Data, AI, and Machining Learning 3 Building an Agile and Scalable Data Science Organization 4 AI and Machine Learning in Drug Discovery 5 Predicting Anti-Cancer Synergistic Activity Through Machine Learning and Natural Language Processing 6 AI-Enabled Clinical Trials 7 Machine Learning for Precision Medicine 8 Reinforcement Learning in Personalized Medicine 9 Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance 10 Intelligent Manufacturing and Supply of Biopharmaceuticals 11 Reinventing Medical Affairs in the Era of Big Data and Analytics 12 Deep Learning with Electronic Health Record 13 Real-World Evidence for Treatment Access and Payment Decisions

Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).

"The book offers a beautiful journey to explore the application of AI and ML in DrugDevelopment. Even though it cannot replace academic courses in AI, ML andhealthcare,authors provide very important and interesting updates regarding the evolution andadvances achieved in this field the past 10 years."Ramzi El Feghali, ISCB News, May 2024.

• 1 Transforming Pharma with Data Science, AI and Machine Learning 2 Regulatory Perspective on Big Data, AI, and Machining Learning 3 Building an Agile and Scalable Data Science Organization 4 AI and Machine Learning in Drug Discovery 5 Predicting Anti-Cancer Synergistic Activity Through Machine Learning and Natural Language Processing 6 AI-Enabled Clinical Trials 7 Machine Learning for Precision Medicine 8 Reinforcement Learning in Personalized Medicine 9 Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance 10 Intelligent Manufacturing and Supply of Biopharmaceuticals 11 Reinventing Medical Affairs in the Era of Big Data and Analytics 12 Deep Learning with Electronic Health Record 13 Real-World Evidence for Treatment Access and Payment Decisions